A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

General Key Inclusion Criteria:

1. Histologically confirmed stage II through IIIB (N2) NSCLC, that is consideredresectable with curative intent, as described in the protocol

2. Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST)criteria version 1.1

3. Available formalin-fixed paraffin-embedded (FFPE) tumor sample blocks forsubmission, as described in the protocol

4. Eastern Cooperative Oncology Group Performance Status scale (ECOG PS) of 0 to 1

5. Adequate organ and bone marrow function, as described in the protocol

General Key Exclusion Criteria:

1. Any systemic anti-cancer therapy or radiotherapy for the current tumor, as describedin the protocol

2. Presence of known oncogenic alterations in epidermal growth factor receptor (EGFR)or anaplastic lymphoma kinase (ALK) in the tumor prior to randomization, asdescribed in the protocol

3. Presence of ≥ grade 2 peripheral neuropathy

4. Another malignancy that is progressing or requires active treatment, as described inthe protocol

Arm Specific Exclusion Criteria:

Arm 1:

1. Grade ≥3 hypercalcemia, as defined in the protocol

2. Any central nervous system (CNS) pathology that could increase the risk of immuneeffector cell-associated neurotoxicity syndrome (ICANS), as described in theprotocol

3. Has marked baseline prolongation of the time from the start of the Q wave to the endof the T wave in electrocardiogram(QT)/corrected QT interval (QTc) interval or riskfactors for prolonged QTc, as described in the protocol

Note: Other protocol-defined Inclusion/Exclusion criteria apply.